Stories

Short versions of Eventris's medical stories and MHRA drug-safety alerts. The full ones are on eventris.app.

Finasteride and Dutasteride: Updated Psychiatric and Sexual Dysfunction Warnings

The MHRA has completed a review of finasteride and dutasteride, two commonly prescribed medications for benign prostatic hyperplasia and male-pattern hair loss, and has identified important new safety information regarding psychiatric side effects and sexual dysfunction. The MHRA has reviewed…

Nasal Decongestant Sprays: Rebound Congestion and Overuse Risk

The MHRA has issued a safety alert regarding nasal decongestant sprays and drops containing xylometazoline hydrochloride and oxymetazoline hydrochloride. Reports indicate an increased risk of rebound congestion, rhinitis medicamentosa, and tachyphylaxis when these products are overused. Rebound…

IXCHIQ Chikungunya Vaccine Temporarily Restricted in Adults Aged 65+

The Commission on Human Medicines (CHM) has temporarily restricted the use of IXCHIQ Chikungunya vaccine in people aged 65 years and over following very rare but serious adverse events reported globally. This is a precautionary measure to allow further investigation. IXCHIQ should not be…

IXCHIQ Chikungunya vaccine: age restrictions updated following safety review

The MHRA has completed a safety review of IXCHIQ (chikungunya vaccine) and, following recommendations from the Commission on Human Medicines (CHM), important changes to its licensed indications have been made. IXCHIQ is no longer indicated for adults over 60 years of age The vaccine is…

GLP-1 Agonists: Strengthened Warnings on Acute Pancreatitis Risk

The MHRA has issued updated safety guidance on GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists, with strengthened warnings regarding the risk of acute pancreatitis, including necrotising and fatal cases. Product information for all GLP-1 and GLP-1/GIP agonists has been updated to…

Isotretinoin prescribing guidance and risk minimisation updates

The Commission on Human Medicines (CHM) has endorsed changes to the risk minimisation measures for isotretinoin following a review of measures implemented in 2023. Healthcare professionals are asked to review the updated guidance to ensure safe prescribing and patient management. Risk minimisation…

Updated Safety Information for Gabapentinoids, Benzodiazepines and Z-Drugs

The MHRA has completed a comprehensive review of safety information supplied with gabapentinoids (pregabalin and gabapentin), benzodiazepines, and z-drugs. The review examined warnings relating to addiction, dependence, withdrawal, and tolerance to ensure prescribers and patients have clear,…

Rybelsus (semaglutide) formulation transition and medication error risk

The MHRA has issued a safety alert regarding a planned transition to a new formulation of Rybelsus® (semaglutide tablets). During this transition period, both the original and new formulations will be in circulation. Although bioequivalent, they carry different stated mg doses, creating a…

#MedSafetyWeek 2025: Collective Action to Improve Medicines Safety

The MHRA is launching its annual #MedSafetyWeek campaign from 3 to 9 November 2025, with a clear message: we can all help make medicines safer. This year's campaign emphasises that medicines safety is not the responsibility of regulators and healthcare professionals alone. Patients, carers,…

RSV Vaccines and Guillain-Barré Syndrome Risk in Older Adults

The MHRA has identified a small but increased risk of Guillain-Barré syndrome (GBS) following vaccination with two RSV vaccines in adults aged 60 years and older. Healthcare professionals should be alert to this potential adverse effect and ensure appropriate patient counselling and monitoring. A…

Valproate Reproductive Risk: Updated Safety Materials Now Available

The MHRA has published updated safety and educational materials to support healthcare professionals and patients in discussing the reproductive risks associated with valproate medicines. These resources implement regulatory measures announced in the November 2023 National Patient Safety Alert and…

Kaftrio: Psychological Side Effects in Cystic Fibrosis Treatment

The MHRA has issued a safety update regarding psychological side effects reported in patients with cystic fibrosis treated with Kaftrio. While these effects are infrequent, healthcare professionals should be aware of the risk profile and monitor patients accordingly. Psychological side effects…

SABA Overuse in Asthma: Safety Reminder and Prescribing Guideline Changes

Healthcare professionals and patients are reminded of the significant risks associated with overuse of short-acting beta 2 agonists (SABA) in asthma management. The MHRA has issued this alert to reinforce existing safety guidance and highlight recent changes to SABA prescribing recommendations.…

All alerts on eventris.app

About these alerts

General information for event medical professionals. Not a substitute for the MHRA alert itself, the SPC, BNF or local clinical guidelines. Each full alert on eventris.app links to its MHRA source.